| | Authors (publication year) | Age of patientsa | Age limitation | Comorbidities (reported)b | Excluded comorbidities | Diabetic status | Histologyc | Metastasis at diagnosis | Stages |
| | Ahmed (2015) | 65 (24–86) | NA | COPD, hypertension, CAD, HLD, and CHF | NA | Mixed | AD, SCC, LCC, poorly differentiated carcinoma, and NSCLC NOS | Limited to one distant metastasis | I–IV | | Lin (2015) | 72.2 (4.0) | 65–80 | Charlson Comorbidity Index | Stage IV–V CKD, end-stage renal disease | Yes | AD, SCC, LCC, and NSCLC NOS | Yes without limitation | IV | | Sayed (2015) | 56 (44–70) | 18–80 | NA | Diabetes, others such as CHF and chronic lung disease with hyposia | No | AD, SCC, LCC | Yes without limitation | IV | | Wink (2016) | 63 (29–87) | NA | NA | NA | Yes | AD, SCC, NSCLC NOS | No | II, III | | Xin (2018) | NA | NA | NA | NA | Yes | AD, SCC | Yes without limitation | NA | | Marrone (2018) | 58 (37–74) | ≥18 | NA | Diabetes, hypertension (>150/>100), history of hemoptysis, thrombotic, and hemorrhagic disorders | No | Nonsquamous NSCLC | Yes without limitation | IIIB-IV | | Chuang (2018) | 71.2 (9.4) | 18–90 | Charlson Comorbidity Index | CKD, end-stage renal disease | Yes | NSCLC | NA | I–IV | | Skinner (2021) | 64 (43–86) | NA | NA | NA | No | AD, adenosquamous, SCC, and NSCLC NOS | No | IIIA-IIIB | | Tsakiridis (2021) | 65.9 (8.1) | ≥18 | NA | Diabetes | No | AD, SCC, LCC, and NSCLC NOS | No | III | | Lee (2021) | NA | ≥18 | NA | NA | Mixed | AD, SCC, and NSCLC NOS | Yes without limitation | IIIB-IV | | Wang (2021) | 67.4 (9.5) | NA | CVA, CAD, CHF, COPD, and CRD | NA | Yes | AD | NA | NA |
|
|
aAge was presented as the mean (SD) or median [range]. bCOPD, chronic obstructive pulmonary disease. CAD, coronary artery disease; HLN, hyperlipidemia; CHF, congestive heart failure; CVA, cerebral vascular accident; CKD, chronic kidney disease; cAD, adenocarcinoma; SCC, squamous cell carcinoma; LCC, large cell carcinoma; NSCLC NOS, non-small cell lung cancer not otherwise specific; NA, not available.
|
